Lexicon reports Q2 net loss $44.9M; FDA-approved INPEFA launched, LX9211 advancing

LEXICON PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$0.39 revenue$340,000

FDA approved INPEFA (sotagliflozin) for heart failure across full LVEF range; U.S. launch completed within 30 days.
LX9211 moving into late-stage development for DPNP; Phase 2b dose optimization study starts Q3 2023.
Q2 2023 net loss of $44.9M ($0.22 per share) vs $24.6M ($0.16) in Q2 2022.
SG&A expenses rose to $30.0M from $10.7M due to commercial launch preparations; R&D $14.5M vs $13.4M.
Cash and investments $256.7M as of June 30, 2023, up from $138.4M at Dec 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.